Global Kidney Fibrosis Treatment Market

Kidney Fibrosis Treatment Comprehensive Study by Therapeutics (Angiotensin Converting Enzyme (ACE) Inhibitors, Pirfenidone, Renin Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasopeptidase Inhibitors), End-Use (Clinics, Hospital) Players and Region - Global Market Outlook to 2030

Kidney Fibrosis Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Kidney Fibrosis Treatment
Kidney fibrosis refers to the direct consequence of the kidney's limited capacity to regenerate after injury which results in the formation of excess fibrous connective tissue in the organ in a repetitive way. Increasing prevalence of kidney disorder driving the demand for kidney fibrosis treatment market. For instance, according to Centers for Disease Control and Prevention, kidney disease is the ninth leading cause of death in the United States and Over 30 million people adults in the United States are estimated to have a chronic kidney disorder and most of them are undiagnosed. Further, according to the NHS Blood and Transplant, as of 31st March 2018, 3,272 adult kidney transplants performed in the United Kingdom only. Further, emphasizing on the new clinical trials and treatments for kidney disorders expected to drive the demand for kidney fibrosis treatment over the forecasted period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Kidney Fibrosis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck & Co. (United States), Pfizer Inc. (United States), F. Hoffman-La Roche Ltd. (Switzerland), InterMune Inc. (United States), Galectin Therapeutics (United States), La Jolla Pharmaceutical Company (United States), ProMetic Life-Sciences Inc. (Canada) and BioLine Rx Ltd. (Israel) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Genzyme Corporation (United States) and ProMetic Life Sciences Inc. (Canada).

Segmentation Overview
AMA Research has segmented the market of Global Kidney Fibrosis Treatment market by and Region.



On the basis of geography, the market of Kidney Fibrosis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapeutics, the sub-segment i.e. Angiotensin Converting Enzyme (ACE) Inhibitors will boost the Kidney Fibrosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Use, the sub-segment i.e. Clinics will boost the Kidney Fibrosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emphasizing On New Clinical Trials and Treatments for Kidney Disorders

Market Growth Drivers:
Increasing Geriatric Population and Increasing Number of Patients with Kidney Disorders

Challenges:
Lack of Awareness in the Emerging Countries

Restraints:
Stringent Government Regulations Regarding Kidney Fibrosis Therapeutics and High Cost Associated With Kidney Fibrosis Treatment

Opportunities:
Growing Healthcare Infrastructure in the Developing Economies and Changing Food Habits and Lifestyle Leading to Rising Prevalence of Chronic Disorders

Market Leaders and their expansionary development strategies
In July 2022, Grupo Olmos which is a provider of renal care solutions, declared that the company had acquired renal care business of Diaverum, a renal healthcare provider, that operates in Argentina. This acquisition will strengthen the renal product portfolio of the company.
23rd April 2019, The Kansas legislation is modeled after The Living Donor Protection Act [H.R. 1224 and S. 511] championed by National Kidney Foundation (NKF) and introduced in February in the United States. Kansas has become the seventh state in the country after Maine, Oklahoma, New York Idaho, Maryland, and Arkansas to pass legislation that would protect living organ donors from life insurance discrimination solely based upon their status as donors.
“The legal framework governing organ donation in the United States is built on principles uniquely designed to support the system of transplantation. The primary law governing organ donation in the United States is the Uniform Anatomical Gift Act (UAGA). The UAGA establishes gift law as the central legal principle in the United States opt-in system of organ donation. A gift—in legal terms—is the legally binding voluntary transfer of something from the donor to the donee without payment. Gift law requires three basic elements: donative intent, transfer, and acceptance.”

Key Target Audience
Kidney Fibrosis Therapeutics Providers, Healthcare Institutes, Government Associations, Research Organizations, Market Research Firms and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Therapeutics
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Pirfenidone
  • Renin Inhibitors
  • Angiotensin II Receptor Blockers (ARBs)
  • Vasopeptidase Inhibitors

By End-Use
  • Clinics
  • Hospital

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population
      • 3.2.2. Increasing Number of Patients with Kidney Disorders
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in the Emerging Countries
    • 3.4. Market Trends
      • 3.4.1. Emphasizing On New Clinical Trials and Treatments for Kidney Disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Kidney Fibrosis Treatment, by Therapeutics, End-Use and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Kidney Fibrosis Treatment (Value)
      • 5.2.1. Global Kidney Fibrosis Treatment by: Therapeutics (Value)
        • 5.2.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors
        • 5.2.1.2. Pirfenidone
        • 5.2.1.3. Renin Inhibitors
        • 5.2.1.4. Angiotensin II Receptor Blockers (ARBs)
        • 5.2.1.5. Vasopeptidase Inhibitors
      • 5.2.2. Global Kidney Fibrosis Treatment by: End-Use (Value)
        • 5.2.2.1. Clinics
        • 5.2.2.2. Hospital
      • 5.2.3. Global Kidney Fibrosis Treatment Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Kidney Fibrosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffman-La Roche Ltd. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. InterMune Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Galectin Therapeutics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. La Jolla Pharmaceutical Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ProMetic Life-Sciences Inc. (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BioLine Rx Ltd. (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Kidney Fibrosis Treatment Sale, by Therapeutics, End-Use and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Kidney Fibrosis Treatment (Value)
      • 7.2.1. Global Kidney Fibrosis Treatment by: Therapeutics (Value)
        • 7.2.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors
        • 7.2.1.2. Pirfenidone
        • 7.2.1.3. Renin Inhibitors
        • 7.2.1.4. Angiotensin II Receptor Blockers (ARBs)
        • 7.2.1.5. Vasopeptidase Inhibitors
      • 7.2.2. Global Kidney Fibrosis Treatment by: End-Use (Value)
        • 7.2.2.1. Clinics
        • 7.2.2.2. Hospital
      • 7.2.3. Global Kidney Fibrosis Treatment Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Kidney Fibrosis Treatment: by Therapeutics(USD Million)
  • Table 2. Kidney Fibrosis Treatment Angiotensin Converting Enzyme (ACE) Inhibitors , by Region USD Million (2018-2023)
  • Table 3. Kidney Fibrosis Treatment Pirfenidone , by Region USD Million (2018-2023)
  • Table 4. Kidney Fibrosis Treatment Renin Inhibitors , by Region USD Million (2018-2023)
  • Table 5. Kidney Fibrosis Treatment Angiotensin II Receptor Blockers (ARBs) , by Region USD Million (2018-2023)
  • Table 6. Kidney Fibrosis Treatment Vasopeptidase Inhibitors , by Region USD Million (2018-2023)
  • Table 7. Kidney Fibrosis Treatment: by End-Use(USD Million)
  • Table 8. Kidney Fibrosis Treatment Clinics , by Region USD Million (2018-2023)
  • Table 9. Kidney Fibrosis Treatment Hospital , by Region USD Million (2018-2023)
  • Table 10. South America Kidney Fibrosis Treatment, by Country USD Million (2018-2023)
  • Table 11. South America Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 12. South America Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 13. Brazil Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 14. Brazil Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 15. Argentina Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 16. Argentina Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 17. Rest of South America Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 18. Rest of South America Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 19. Asia Pacific Kidney Fibrosis Treatment, by Country USD Million (2018-2023)
  • Table 20. Asia Pacific Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 21. Asia Pacific Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 22. China Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 23. China Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 24. Japan Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 25. Japan Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 26. India Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 27. India Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 28. South Korea Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 29. South Korea Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 30. Taiwan Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 31. Taiwan Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 32. Australia Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 33. Australia Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 36. Europe Kidney Fibrosis Treatment, by Country USD Million (2018-2023)
  • Table 37. Europe Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 38. Europe Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 39. Germany Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 40. Germany Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 41. France Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 42. France Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 43. Italy Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 44. Italy Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 45. United Kingdom Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 46. United Kingdom Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 47. Netherlands Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 48. Netherlands Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 49. Rest of Europe Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 50. Rest of Europe Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 51. MEA Kidney Fibrosis Treatment, by Country USD Million (2018-2023)
  • Table 52. MEA Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 53. MEA Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 54. Middle East Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 55. Middle East Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 56. Africa Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 57. Africa Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 58. North America Kidney Fibrosis Treatment, by Country USD Million (2018-2023)
  • Table 59. North America Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 60. North America Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 61. United States Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 62. United States Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 63. Canada Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 64. Canada Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 65. Mexico Kidney Fibrosis Treatment, by Therapeutics USD Million (2018-2023)
  • Table 66. Mexico Kidney Fibrosis Treatment, by End-Use USD Million (2018-2023)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Kidney Fibrosis Treatment: by Therapeutics(USD Million)
  • Table 76. Kidney Fibrosis Treatment Angiotensin Converting Enzyme (ACE) Inhibitors , by Region USD Million (2025-2030)
  • Table 77. Kidney Fibrosis Treatment Pirfenidone , by Region USD Million (2025-2030)
  • Table 78. Kidney Fibrosis Treatment Renin Inhibitors , by Region USD Million (2025-2030)
  • Table 79. Kidney Fibrosis Treatment Angiotensin II Receptor Blockers (ARBs) , by Region USD Million (2025-2030)
  • Table 80. Kidney Fibrosis Treatment Vasopeptidase Inhibitors , by Region USD Million (2025-2030)
  • Table 81. Kidney Fibrosis Treatment: by End-Use(USD Million)
  • Table 82. Kidney Fibrosis Treatment Clinics , by Region USD Million (2025-2030)
  • Table 83. Kidney Fibrosis Treatment Hospital , by Region USD Million (2025-2030)
  • Table 84. South America Kidney Fibrosis Treatment, by Country USD Million (2025-2030)
  • Table 85. South America Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 86. South America Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 87. Brazil Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 88. Brazil Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 89. Argentina Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 90. Argentina Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 91. Rest of South America Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 92. Rest of South America Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 93. Asia Pacific Kidney Fibrosis Treatment, by Country USD Million (2025-2030)
  • Table 94. Asia Pacific Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 95. Asia Pacific Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 96. China Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 97. China Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 98. Japan Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 99. Japan Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 100. India Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 101. India Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 102. South Korea Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 103. South Korea Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 104. Taiwan Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 105. Taiwan Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 106. Australia Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 107. Australia Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 108. Rest of Asia-Pacific Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 109. Rest of Asia-Pacific Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 110. Europe Kidney Fibrosis Treatment, by Country USD Million (2025-2030)
  • Table 111. Europe Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 112. Europe Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 113. Germany Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 114. Germany Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 115. France Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 116. France Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 117. Italy Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 118. Italy Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 119. United Kingdom Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 120. United Kingdom Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 121. Netherlands Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 122. Netherlands Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 123. Rest of Europe Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 124. Rest of Europe Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 125. MEA Kidney Fibrosis Treatment, by Country USD Million (2025-2030)
  • Table 126. MEA Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 127. MEA Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 128. Middle East Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 129. Middle East Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 130. Africa Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 131. Africa Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 132. North America Kidney Fibrosis Treatment, by Country USD Million (2025-2030)
  • Table 133. North America Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 134. North America Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 135. United States Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 136. United States Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 137. Canada Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 138. Canada Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 139. Mexico Kidney Fibrosis Treatment, by Therapeutics USD Million (2025-2030)
  • Table 140. Mexico Kidney Fibrosis Treatment, by End-Use USD Million (2025-2030)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Kidney Fibrosis Treatment: by Therapeutics USD Million (2018-2023)
  • Figure 5. Global Kidney Fibrosis Treatment: by End-Use USD Million (2018-2023)
  • Figure 6. South America Kidney Fibrosis Treatment Share (%), by Country
  • Figure 7. Asia Pacific Kidney Fibrosis Treatment Share (%), by Country
  • Figure 8. Europe Kidney Fibrosis Treatment Share (%), by Country
  • Figure 9. MEA Kidney Fibrosis Treatment Share (%), by Country
  • Figure 10. North America Kidney Fibrosis Treatment Share (%), by Country
  • Figure 11. Global Kidney Fibrosis Treatment share by Players 2023 (%)
  • Figure 12. Global Kidney Fibrosis Treatment share by Players (Top 3) 2023(%)
  • Figure 13. Global Kidney Fibrosis Treatment share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 19. F. Hoffman-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffman-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 21. InterMune Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. InterMune Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Galectin Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 24. Galectin Therapeutics (United States) Revenue: by Geography 2023
  • Figure 25. La Jolla Pharmaceutical Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. La Jolla Pharmaceutical Company (United States) Revenue: by Geography 2023
  • Figure 27. ProMetic Life-Sciences Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 28. ProMetic Life-Sciences Inc. (Canada) Revenue: by Geography 2023
  • Figure 29. BioLine Rx Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 30. BioLine Rx Ltd. (Israel) Revenue: by Geography 2023
  • Figure 31. Global Kidney Fibrosis Treatment: by Therapeutics USD Million (2025-2030)
  • Figure 32. Global Kidney Fibrosis Treatment: by End-Use USD Million (2025-2030)
  • Figure 33. South America Kidney Fibrosis Treatment Share (%), by Country
  • Figure 34. Asia Pacific Kidney Fibrosis Treatment Share (%), by Country
  • Figure 35. Europe Kidney Fibrosis Treatment Share (%), by Country
  • Figure 36. MEA Kidney Fibrosis Treatment Share (%), by Country
  • Figure 37. North America Kidney Fibrosis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck & Co. (United States)
  • Pfizer Inc. (United States)
  • F. Hoffman-La Roche Ltd. (Switzerland)
  • InterMune Inc. (United States)
  • Galectin Therapeutics (United States)
  • La Jolla Pharmaceutical Company (United States)
  • ProMetic Life-Sciences Inc. (Canada)
  • BioLine Rx Ltd. (Israel)
Additional players considered in the study are as follows:
Genzyme Corporation (United States) , ProMetic Life Sciences Inc. (Canada)
Select User Access Type

Key Highlights of Report


Jan 2024 249 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Kidney Fibrosis Treatment Market Quantitative research analysis
Global Kidney Fibrosis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck & Co. (United States), Pfizer Inc. (United States), F. Hoffman-La Roche Ltd. (Switzerland), InterMune Inc. (United States), Galectin Therapeutics (United States), La Jolla Pharmaceutical Company (United States), ProMetic Life-Sciences Inc. (Canada) and BioLine Rx Ltd. (Israel) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emphasizing On New Clinical Trials and Treatments for Kidney Disorders" is seen as one of major influencing trends for Kidney Fibrosis Treatment Market during projected period 2023-2030.
The Kidney Fibrosis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Kidney Fibrosis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Legionella Testing Comprehensive Study by Type (Microbial Culture, DFA Stain, PCR, Others), Application (Water Testing, IVD Testing), End User (Hospital and Clinic, Diagnostic Laboratory) Players and...
$ 3500
Chemotherapy Induced Peripheral Neuropathy Treatment Comprehensive Study by Type (APX-3330, BR-297, Cannabidiol, Dimiracetam, Others), Application (Platinum Agents, Taxanes, Vinca Alkaloids, Others) ...
$ 3500
Animal Therapeutics and Diagnostics Comprehensive Study by Type (Animal Diagnostics Products (Instruments, Consumables), Animal Therapeutics Products (Anti-Parasitic Drugs and Antibiotics, Anti-Infla...
$ 3750
Irritable Bowel Syndrome Treatment Comprehensive Study by Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Ramosetron Hydrochloride, Others), Distribution Channel (Hospital Pharmacies, Online...
$ 3450
Cancer Test Comprehensive Study by Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), Application (Bladder Cancer Test, Breast Cancer Test, Cervical Cancer Test, Colorectal (Colon) Cancer Te...
$ 3650
Dermatological Therapeutics Comprehensive Study by Type (Anti-infectives , Corticosteroids, Anti Psoriasis, Anti-acne , Others), Application (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopec...
$ 3750